Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Authors

Institutions

Publication Details

Journal
CNS Drugs
Published
2024-10-07
DOI
https://doi.org/10.1007/s40263-024-01118-8
Citations
3
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Shannon Strom, Detlef Albrecht, Jessica Ailani, Alan M. Rapoport et al.
3 citations
CNS Drugs
Migraine and Headache Studies
1.16
article

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Shannon Strom, Detlef Albrecht, Jessica Ailani, Alan M. Rapoport, Stewart J. Tepper, Louis Kirby
article en
3 citations

Abstract

No abstract available for this paper.
CNS DrugsVol. 38(12)
University of California, Los Angeles (US), Georgetown University (US), Paradise Valley Community College (US), New England Institute for Neurology and Headache (US), Inspire Institute (US)
Good health and well-being
Openalex Percentile: Top 20%
Migraine and Headache Studies
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.